中国生物制药国产贴剂破局阿尔茨海默病慢病管理

动脉网
Oct 01, 2025

今年世界脑健康日聚焦“全生命周期的脑健康”,我国60岁以上人群中,阿尔茨海默病患者高达1000万,患病率与死亡率均超全球平均水平,年支出高达1.2万亿元。患者饱受记忆丧失等痛苦,早期筛查与科学干预可维持患者基本自理能力。中国生物制药旗下北京泰德制药依托自研透皮技术平台,成功研发国产首款利斯的明透皮贴剂“苏乐达®”,为阿尔茨海默病慢病管理开辟新路径。该贴剂通过抑制乙酰胆碱降解改善认知功能,透皮给药...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10